Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.

The short-term, real-world incidences of abnormal laboratory results or adverse events were consistent with the pivotal clinical trial findings. Longer-term safety data are still needed.